1 Profiling cases with non-respiratory symptoms and asymptomatic SARS-CoV-2

2 infections in Mexico City

- 3 Omar Yaxmehen Bello-Chavolla MD, PhD1*, Neftali Eduardo Antonio-Villa MD2, Arsenio
- 4 Vargas-Vázquez², Carlos A. Fermín-Martínez², Alejandro Márquez-Salinas², Jessica Paola
- 5 Bahena-López MD²
- 6
- ⁷ ¹Division of Research, Instituto Nacional de Geriatría. ²MD/PhD (PECEM), Faculty of
- 8 Medicine, National Autonomous University of Mexico.
- 9
- 10 Short title: Asymptomatic SARS-CoV-2 in Mexico City
- 11

12 Corresponding author

- 13 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriatría. Anillo
- 14 Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico.
- 15 Phone: +52 (55) 5548486885. E-mail: <u>oyaxbell@yahoo.com.mx</u>
- 16 **CONFLICT OF INTERESTS:** Nothing to disclose.

17

18 Word count: 1,496 words; 2 Figures.

19 ABSTRACT (50 WORDS)

We profiled cases with non-respiratory symptoms (NRS) and asymptomatic SARS-CoV-2 assessed within Mexico City's Epidemiological Surveillance System. We show that initially asymptomatic or NRS cases have decreased risk of adverse COVID-19 outcomes compared to cases with respiratory symptoms. Comorbidity and age influence likelihood of developing symptoms in initially asymptomatic cases.

26 **Keywords:** SARS-CoV-2; Asymptomatic; Pre-symptomatic; Mexico; COVID-19 outcomes

28 INTRODUCTION

Asymptomatic infections are a potential source of rapid SARS-CoV-2 spread¹. Prevalence of 29 30 pre-symptomatic/asymptomatic cases varies widely but represent a larger proportion of cases than previously anticipated ². Controversies surrounding asymptomatic SARS-CoV-2 31 infections have focused on the distinction between pre-symptomatic and asymptomatic 32 33 infection and its definitions; nevertheless, longitudinal data shows that only a fraction of initially asymptomatic infections develop subsequent symptoms ^{3,4}. In Mexico, SARS-CoV-2 34 testing focuses on sampling high-risk cases with suspected COVID-19 by the presence of 35 36 RS, which has allowed characterization of increased susceptibility for severe COVID-19 attributable to cardio-metabolic comorbidities ⁵; however, no data has been reported on cases 37 38 with non-respiratory symptomatology (NRS) and asymptomatic SARS-CoV-2 infections, 39 which are underrepresented under the current testing framework in Mexico. Lack of 40 information regarding cases with NRS, or initially asymptomatic cases in Mexico is 41 concerning, particularly since many studies suggest that contact tracing of asymptomatic 42 infections will be pivotal to contain further SARS-CoV-2 spread and the likelihood of underreporting cases without respiratory symptoms but with NRS⁶. Here, we profile patients 43 with NRS and initially asymptomatic SARS-CoV-2 infections to assess outcomes after follow-44 45 up using cases detected in Mexico City.

46 **METHODS**

We analyzed data from the National Epidemiological Surveillance System in the Greater Mexico City area, an open-source dataset comprising daily updated cases tested using realtime RT-PCR to confirm SARS-CoV-2 using nasopharyngeal swabs according to the Berlin Protocol ⁷. For analysis, we propose two main symptom groups, which we confirmed using correspondence analyses to cluster symptoms with comparable similarity (**Supplementary Material**): RS included dyspnea, polypnea or cyanosis at initial evaluation, but we also included fever and cough in this group based on WHO criteria for suspected COVID-19

54 cases; whilst NRS included headache, myalgias, arthralgias, general malaise, abdominal 55 pain, chest pain, conjunctivitis, irritability or vomiting. We defined cases with RS as those with 56 ≥1 RS and any or none NRS. Cases with NRS had ≥1 NRS without any RS, whilst initially 57 asymptomatic cases had no symptoms at the point of initial assessment. NRS and initially asymptomatic cases were assessed outside the established framework for suspected 58 59 COVID-19 cases in Mexico by contact tracing of real-time RT-PCR confirmed SARS-CoV-2 60 infection and convenience sampling of cases without symptoms who requested an RT-PCR 61 test for SARS-CoV-2; complete description of the Mexican testing framework is described in 62 Supplementary Material. We also estimated 7-day rolling average positivity rates (PR) for RS, NRS and initially asymptomatic cases. Follow-up was conducted for all non-hospitalized 63 64 cases up to 14 days; outcomes for all patients included hospital discharge due to clinical 65 improvement or voluntary, ambulatory/treatment follow-up or death; additional information 66 regarding follow-up is presented in Supplementary Material. Severe COVID-19 was defined 67 as a composite of death, ICU admission or intubation. Complete description of statistical 68 analyses and available variables are detailed in **Supplementary Material**.

69 **RESULTS**

70 <u>Study population</u>

As of 19th August 2020, a total of 296,157 subjects were tested for SARS-CoV-2 in Mexico 71 72 City. From 108,080 cases with confirmed SARS-CoV-2 infection (PR 36.5%), 14,657cases did not have RS (13.6%). Overall, 37,356 NRS cases had been evaluated, amongst whom 73 74 8,545 had confirmed SARS-CoV-2 infection (Overall PR: 22.9%); similarly, 35,175 initially asymptomatic cases were evaluated and 6,112 cases had confirmed SARS-CoV-2 infection 75 76 (PR: 17.4%). Seven-day PRs had been steadily decreasing for all patient categories during 77 the last few weeks (Supplementary Material). NRS cases were younger, predominantly female and had lower prevalence of NRS compared to cases with RS. Initially asymptomatic 78

cases were younger compared to RS cases, with similar trends for lower rates of
 comorbidities compared to both RS and NRS cases (Figure 1).

81 Profiling NRS cases with SARS-CoV-2 infection

82 Amongst NRS cases (n=8,545), 365 subjects were hospitalized (4.3%), 32 required mechanical ventilatory support (MVS) (0.4%), 32 required intensive care unit (ICU) admission 83 84 (0.4%). Overall, 112 patients died (1.3%), of whom 24 deaths were ambulatory (0.3%) and 88 hospitalized (1.0%). Predictors that increased risk for severe COVID-19 in NRS cases 85 86 included age >60 years, chronic obstructive pulmonary disease (COPD), diabetes, and 87 chronic kidney disease (CKD); decreased risk of severe COVID-19 was associated with rhinorrhea, previous exposure to suspected viral cases and healthcare workers. Independent 88 89 predictors of mortality in NRS included age >60 years, diabetes, COPD, CKD, and decreased 90 risk associated with previous exposure to suspected viral cases (Supplementary Material). 91 After follow-up, 530 patients were still under domiciliary surveillance (6.2%), 127 remained 92 hospitalized (1.5%), 146 were discharged after recovery (1.7%), 4 had voluntary discharge 93 and 7,626 had completed follow-up with domiciliary surveillance without developing RS 94 (89.2%).

95 Profiling initially asymptomatic cases with SARS-CoV-2 infection

96 Amongst initially asymptomatic patients with SARS-CoV-2 infection (n=6,112), 185 were 97 eventually hospitalized (3.0%), 12 required MVS (0.2%) and 29 required ICU admission (0.5%). We recorded 32 deaths (0.5%) amongst whom 11 deaths were ambulatory (0.2%) 98 and 21 were hospitalized (0.3%). Predictors for severe COVID-19 included age >60 years, 99 CKD, and reduced risk associated to previous exposure to suspected viral cases; predictors 100 of lethality included age >60 years and CKD. As of August 19th 2020, 415 patients were still 101 102 under domiciliary surveillance (6.8%), 91 remained hospitalized (1.5%), 71 were discharged 103 after recovery (1.2%), 2 had a voluntary discharge, and 5,501 had completed follow-up 104 without developing symptoms which required hospitalization (90.0%).

105 *Predictors and outcomes for RS, NRS and asymptomatic cases*

106 Compared to initially asymptomatic cases, symptomatic cases were associated with older 107 age, reduced previous viral exposure, healthcare workers, diabetes, obesity, hypertension, 108 CKD, COPD, asthma and smoking. Similarly, compared to NRS, RS cases were associated 109 with asthma, immunosuppression, COPD, older age, male sex, diabetes, obesity, 110 hypertension, reduced previous viral exposure with a reduced likelihood associated with smoking (Figure 2). Compared to initially asymptomatic cases, risk of severe COVID-19 was 111 significantly higher for both NRS (HR 1.56, 95%CI 1.14-2.13) and RS cases (HR 4.78, 95%CI 112 113 3.67-6.21), adjusted for age, sex and comorbidities. Similarly, NRS and RS had higher 114 mortality compared to asymptomatic cases (Breslow-Cox p<0.001, Figure 2); adjusting for 115 age, sex and comorbidities, NRS (HR 2.32, 95%CI 1.57-3.43) or RS cases (HR 6.50, 95%CI 116 4.59-9.21) retained higher mortality compared to initially asymptomatic cases.

117 **DISCUSSION**

118 Here, we present a comprehensive report of COVID-19 cases with NRS and initially 119 asymptomatic SARS-CoV-2 infections in Mexico City. Early detection of SARS-CoV-2 120 infections in initially asymptomatic patients or who present with NRS would help to reduce the spread of SARS-CoV-2 in Mexico, as these patients have lower risk of subsequent 121 122 complications, as shown in this study, and would benefit the most from domiciliary treatment 123 and prompt isolation. We also report a low prevalence of cases who were initially classified as 124 asymptomatic but eventually were hospitalized or had outcomes related to severe COVID-19⁸. This data confirms observations from other populations regarding the course of COVID-125 19 cases with NRS and initially asymptomatic SARS-CoV-2 infections³. Our study also 126 127 highlights the relevance of extending testing to cases with NRS and initially asymptomatic 128 cases within the testing framework in Mexico; identifying asymptomatic cases is of 129 importance given conflicting evidence on viral shedding for these cases, and data suggesting 130 evidence of subclinical lung abnormalities which must be assessed longitudinally to rule out

131 long-term impacts of SARS-CoV-2 infection ⁹. Notably, a consistent predictor of outcomes for 132 NRS cases and initially asymptomatic cases were previous exposure to suspected viral 133 cases, highlighting the relevance of contact tracing and prompt case identification but also 134 confirming that cases presented in our study are not representative of all asymptomatic 135 infections but mostly of those identified by contact tracing, likely underestimating rates of true 136 asymptomatic cases.

Studies assessing natural history of initially asymptomatic SARS-CoV-2 infections highlighted 137 the role of age and comorbidity in the subsequent development of symptoms, which is 138 consistent with our observations¹⁰. Domiciliary surveillance in Mexico City focused on 139 140 outcomes but not individual symptom onset, which might limit our ability to adequately 141 characterize pre-symptomatic cases, particularly those who only develop mild symptoms and 142 do not require hospital admission. Regardless, only a small fraction of initially asymptomatic 143 cases developed severe COVID-19 after initial assessment, most of whom had underlying 144 chronic comorbidities or were susceptible for COVID-19 complications attributable to 145 unmasked cardiometabolic comorbidities. The eventual presentation of severe COVID-19 in 146 initially asymptomatic cases might be attributable to a combination of decreased early immune response to SARS-CoV-2 infection and late enhanced pro-inflammatory responses 147 in subjects with comorbidities ^{9,11}. This might also extend to subjects with NRS with COVID-148 149 19 whom have previously been reported to delay seeking medical attention and have prolonged viral shedding compared with subjects with RS only ¹². 150

Here, we assessed a thorough constellation of symptoms in one of the largest studies of NRS and initially asymptomatic SARS-CoV-2 infections. Additional limitations include nonassessment of atypical SARS-CoV-2 symptoms which might occur amongst otherwise asymptomatic cases, particularly in older adults, and the lack of systematized sampling, which does not allow for an accurate estimation for the rates of asymptomatic cases in Mexico City. Our results highlight the need to systematize definitions of asymptomatic cases

and extend testing by contact tracing to detect asymptomatic SARS-CoV-2 infections as one
 of the mitigations strategies to reduce transmission of SARS-CoV-2 in Mexico City and
 Mexico in general.

160

161 **ACKNOWLEDGMENTS**

NEAV, JPBL, and AVV are enrolled at the PECEM program of the Faculty of Medicine at UNAM. JPBL and AVV are supported by CONACyT. The authors would like to acknowledge the invaluable work of all of Mexico's healthcare community in managing the COVID-19 epidemic. Its participation in the COVID-19 surveillance program has made this work a reality, we are thankful for your effort.

167 **DATA AVAILABILITY**

168 All data sources and R code are available for reproducibility of results at 169 https://github.com/oyaxbell/covid asymptomatic cdmx.

170 AUTHOR CONTRIBUTIONS

Research idea and study design OYBC, NEAV, AVV, JPBL, CAFM, AMS; data acquisition: OYBC; data analysis/interpretation: OYBC, JPBL, NEAV, AVV, CAFM, AMS; statistical analysis: OYBC; manuscript drafting: OYBC, NEAV, AVV, JPBL, CAFM, AMS; supervision or mentorship: OYBC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions about the accuracy or integrity of any portion of the work are appropriately investigated and resolved.


FUNDING: This project was supported by a grant from Secretaría de Educación, Ciencia,
Tecnología e Innovación de la Ciudad de México CM-SECTEI/041/2020 "Red Colaborativa
de Investigación Traslacional para el Envejecimiento Saludable de la Ciudad de México
(RECITES)".

182 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

184 **REFERENCES**

- Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, et al. The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis. *medRxiv*. April
 2020. doi:10.1101/2020.04.25.20079103
- Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative
 Review. Ann Intern Med. June 2020. doi:10.7326/M20-3012
- Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2
 Infection. *N Engl J Med*. June 2020. doi:10.1056/NEJMc2013020
- Imperial College COVID-19 Response Team, Lavezzo E, Franchin E, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo. *Nature*. June 2020. doi:10.1038/s41586-020-2488-1
- Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, et al. Predicting mortality due
 to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19
 outcomes in Mexico. *J Clin Endocrinol Metab.* May 2020. doi:10.1210/clinem/dgaa346
- Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies. *Clin Infect Dis.* May 2020.
 doi:10.1093/cid/ciaa654
- Covid-19 SINAVE Ciudad de México Datos CDMX.
 https://datos.cdmx.gob.mx/explore/dataset/base-covid-sinave/table/. Accessed June 28,
 202
 2020.
- Meng H, Xiong R, He R, et al. CT imaging and clinical course of asymptomatic cases
 with COVID-19 pneumonia at admission in Wuhan, China. *J Infect*. 2020;81(1):e33-e39.
 doi:10.1016/j.jinf.2020.04.004
- Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of
 asymptomatic SARS-CoV-2 infections. *Nat Med.* June 2020. doi:10.1038/s41591-020 0965-6
- 10. [2006.08471] Probability of symptoms and critical disease after SARS-CoV-2 infection.
 https://arxiv.org/abs/2006.08471. Accessed June 28, 2020.
- Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms
 of immunopathological changes in COVID-19. *Allergy*. May 2020. doi:10.1111/all.14364
- Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild
 Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J
 Gastroenterol. 2020;115(6):916-923. doi:10.14309/ajg.00000000000664


218 FIGURE LEGENDS



219

FIGURE 1. Histogram comparing case distribution according to age groups comparing cases with RS, NRS and asymptomatic SARS-CoV-2 infection, demonstrating the role of age in determining asymptomatic SARS-CoV-2 infections (A). We also show a

- comparison of the distribution of NRS related to SARS-CoV-2 infections in subjects with RS and NRS only. *p<0.001
- 223 <u>Abbreviations</u>: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; Sudden onset: Patient report of sudden onset of 224 symptomatology.
- 225



227

FIGURE 2. Factors associated with presence of RS compared to NRS, and RS/NRS compared to asymptomatic cases with SARS-CoV-2 infection (A). We also show the and comparison of 30-day mortality rates between RS cases, NRS and asymptomatic SARS-CoV-2 infections in Mexico City (B).

231 <u>Abbreviations</u>: RS: Respiratory symptoms; NRS: Non-respiratory Symptoms; COPD: Chronic obstructive pulmonary disease; CKD: 232 Chronic kidney disease; HCW: Health-care workers; Previous viral exposure: Prior contact with a patient with suspected viral 233 infection.